Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep773 | Pituitary: clinical | ECE2015

Clinical characterisation of acromegaloidism in a controlled prospective study

Catalina Pablo F , Guanipa Wilfredo , Paramo Concepcion , Gonzalez Enrique Suarez , Matias Lucas Gonzalez , Alvarez Elias , Mallo Federico

Acromegaloidisms are usually reported as isolated cases that are not well characterised clinically. Indeed, most such cases were reported several decades ago, part of the reason why our knowledge about this entity is scarce. By contrast, clinical situations suggestive of acromegaly are not so infrequent, in which basal GH and IGF1 levels lie within a normal range, the GH responses to OGTT challenge are conserved and there is no radiological (MRI) evidence of hypothalamic-pitui...

ea0049ep365 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2017

Salivary lactate levels during anaerobic threshold (AT) training

Berea Hugo Ogando , Estevez Laura Toba , Gomez Juan Fandino , Chaves Yolanda Diz , Soidan Jose Luis Garcia , Matias Lucas Gonzalez , Ferrer Federico Mallo

Anaerobic threshold (AT) is defined as the point of maximum intensity at which lactate is being produced but does not accumulate in blood during exercise. Training at this intensity is common in athletes. Lactate is currently regard as indicator of effort intensity. It is usually quantified by reflectometry of capillary blood. This procedure although not very invasive, may be annoying during repeated measurements. Saliva is proposed as an alternative sample.<p class="abste...

ea0037ep620 | Obesity and cardiovascular endocrinology | ECE2015

Liraglutide improves surfactant protein-B production and reduces right ventricular hypertrophy in a rat model of intersitial pulmonary fibrosis

Gomez Juan Fandino , Perez Marina Romani , Iglesias Veronica Outeirino , Chaves Yolanda Diz , Nunez Maria Gonzalez , Dab Houcine , Gago Eva MariaVigo , Matias Lucas Gonzalez , Ferrer Federico Mallo

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal lung disease characterized by excessive matrix deposition that disrupts the normal alveolar architecture and lung physiology. Glucagon-like peptide 1 (GLP1) is a gut-produced hormone with insulinotropic effects. GLP1 receptor is expressed in the lung where it is implicated in the synthesis of the protein (SPs) and lipid fractions of the surfactant. We have previously shown that the GLP1 receptor agonist, l...